Polypeptide With Localisation/Targeting Motif TRIZ Cases

Segmenting heavy chains into single units with dual variable domains improves bispecific functionality while maintaining molecule stability.

Sortase A enzymatic conjugation assembles multispecific polypeptides in vivo, resolving systemic toxicity and off-target distribution.

A fusion polypeptide links a B5R membrane addressing peptide to an ORF2 antigenic domain.

Endothelial hemoglobin alpha mediates nitric oxide signaling to resolve contradictions between model simplicity and biochemical accuracy.

Genetically engineered hypoimmunogenic cells with reduced MHC and overexpressed CD47 enable repeated dosing without immunosuppression.

Engineered signal peptides direct recombinant proteins out of mammalian host cells to resolve secretion inefficiencies and intracellular toxicity.

Engineered receptors lacking signaling residues block ligand binding, reducing immunosuppression without dose-limiting toxicity.

Engineered regulatory T cells with DPP6-specific chimeric antigen receptors suppress autoimmune attacks to preserve pancreatic beta cell mass.

Administering DGK inhibitors alongside T cell therapy prevents exhaustion, sustaining therapeutic efficacy.

Genetically modified T cells express chimeric antigen receptors targeting HBV antigens, reducing viral loads and side effects compared to interferon therapy.

Engineered immune cells express CS1-specific chimeric antigen receptors to detect and eradicate myeloma tumor cells.

Engineered hNGAL muteins bind small molecules with high affinity through specific amino acid substitutions.

Extracting the variable heavy chain reduces molecular weight and immunogenicity while maintaining antigen binding function.

MiniNotch receptors omit negative regulatory regions to reduce size and improve expression while maintaining ligand-dependent activation.

Merging TACI and BCMA binding domains into one CAR construct increases killing efficacy against multiple myeloma while managing construct complexity.

Engineered yeast cells co-express endoglucosaminidase to deglycosylate glycoproteins within the same system.

Engineered shell proteins incorporate iron-sulfur clusters to enable electron transfer across bacterial microcompartments.

A hybrid protein combines cell penetrating peptides and DNA binding domains to deliver genetic material into target cells.

Variant signal peptides with increased average hydrophobicity drive heterologous polypeptide secretion across the bacterial inner membrane.

Framework mutations in a humanized anti-HER3 antibody reduce immunogenicity while preserving binding affinity for HER3-positive tumors.

Chimeric antigen receptors targeting glucose-regulated protein 78 overcome variable antigen expression to treat diverse malignancies.

Switchable fusion polypeptides modulate CAR-T cell activity via dynamic signaling to reduce toxicity while enhancing therapeutic efficacy.

A CasX:gNA system modifies the C9orf72 gene to reduce toxic RNA accumulation.

A pH-dependent antibody utilizes histidine residues in complementarity determining regions to modulate binding affinity for targeted delivery.

Humanized anti-MUC1* antibodies bind the cleaved extracellular domain of MUC1 to block receptor activation.

Non-cleavable linkers in extracellular drug conjugates prevent premature release, reducing off-target toxicity while maintaining selective CD38 binding.

Engineered T cells target ropporin-1A and ropporin-1B epitopes to kill solid tumors while minimizing treatment-related toxicities.

Truncated enzyme sequences with enhanced EF-hand motifs resolve the contradiction between molecular weight reduction and luminescence stability.

A truncated influenza hemagglutinin vaccine targets the conserved stalk domain to elicit robust immune responses.

Fusing insulin with a feline IgG2 Fc fragment extends serum half-life beyond three days, reducing injection frequency from daily to weekly.

Engineered CAR cells express extracellular domains binding SIGLEC15 or kisspeptin receptors, enabling selective tumor destruction while sparing normal tissues.

A modified Pseudomonas exotoxin A substitutes specific amino acid residues to lower immunogenicity while preserving cytotoxic activity.

Dual-function immunoresponsive cells combine antigen recognition with TRAIL secretion to overcome solid tumor heterogeneity and resistance.

A fusion peptide increases the distance between endoplasmic reticulum and mitochondria to induce intracellular autophagy.

CAR-expressing macrophages target FAP on senescent cells, resolving tissue infiltration limits and inflammatory side effects of prior therapies.

Recombinant viral vector delivers a modified human metapneumovirus F protein antigen to elicit neutralizing antibodies.

Polynucleotides encoding fusion proteins with CD40 domains accelerate T cell response speed against solid tumors while reducing immunosuppressive signals.

A CD19 chimeric antigen receptor integrates CD28 costimulatory domains to drive T cell expansion and cytotoxic activity.

Expressing IL-10 in CAR T cells restores mitochondrial respiration, overcoming exhaustion in solid tumor microenvironments.

Smaller Cas9 orthologs enable single AAV vector delivery of multiple guide RNAs, eliminating dual-vector complexity and reducing manufacturing costs.

Transgenic microalgae encapsulate biologically active proteins within vacuoles to maintain structural integrity during oral administration.

Antibody-derived constructs integrate costimulatory domains to enhance T cell targeting specificity, reducing on-target off-tumor toxicity in cancer therapies.

Fusing minimal catalytic domains with transmembrane peptides creates chimerical glycosyltransferases that boost recombinant protein production.

Chimeric beta(1,4)-galactosyltransferase expression modifies plant N-glycans to produce bi-antennary structures.

Segmenting the CAR receptor with NKp30 domains creates composite signaling that forms stable immune synapses, reducing cytokine release syndrome.

Chimeric transmembrane proteins with suicide modules enable selective cell depletion to prevent graft versus host disease and cytokine release syndrome.

A PSD-95 inhibitor blocks protein binding to reduce infarct volume and neurocognitive deficits in stroke patients.

Optimized CAR spacer domain prevents activation-induced cell death, resolving the contradiction between target specificity and in vivo persistence.

Periplasmic anchor proteins display antibodies in the yeast periplasmic space to select functional variants that modulate target membrane proteins.